Antisense modulation of glioma-associated oncogene-1 expression
US6329203A · kind A · utility
21Cited by
1References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 8, 2000 |
| Grant date | Dec 11, 2001 |
| Priority date | — |
| Expiry date | Sep 8, 2020 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02P20/582
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of glioma-associated oncogene-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding glioma-associated oncogene-1. Methods of using these compounds for modulation of glioma-associated oncogene-1 expression and for treatment of diseases associated with expression of glioma-associated oncogene-1 are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.